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BACKGROUND: HMGA1 is a non-histone nuclear protein that regulates cellular proliferation, invasion and apoptosis
and is overexpressed in many carcinomas. In this study we sought to explore the expression of HMGA1 in HCCs and
cirrhotic tissues, and its effect in in vitromodels.METHODS:WeevaluatedHMGA1 expression using gene expression
microarrays (59 HCCs, of which 37 were matched with their corresponding cirrhotic tissue and 5 normal liver donors)
and tissue microarray (192 HCCs, 108 cirrhotic tissues and 79 normal liver samples). HMGA1 expression was
correlated with clinicopathologic features and patient outcome. Four liver cancer cell lines with stable induced or
knockdown expression of HMGA1 were characterized using in vitro assays, including proliferation, migration and
anchorage-independent growth. RESULTS: HMGA1 expression increased monotonically from normal liver tissues to
cirrhotic tissue to HCC (P b .01) and was associated with Edmondson grade (P b .01). Overall, 51% and 42%of HCCs
and cirrhotic tissues expressed HMGA1, respectively. Patients with HMGA1-positive HCCs had earlier disease
progression and worse overall survival. Forced expression of HMGA1 in liver cancer models resulted in increased cell
growth and migration, and vice versa. Soft agar assay showed that forced expression of HMGA1 led to increased foci
formation, suggesting an oncogenic role of HMGA1 in hepatocarcinogenesis. CONCLUSIONS: HMGA1 is frequently
expressed in cirrhotic tissues and HCCs and its expression is associated with high Edmondson grade and worse
prognosis in HCC. Our results suggest that HMGA1may act as oncogenic driver of progression, implicating it in tumor
growth and migration potential in liver carcinogenesis.
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HMGA1 is a non-histone nuclear protein involved in cell
cycle-related chromosomal changes, genetic recombination, DNA
replication and repair, apoptosis, and molecular chaperoning [1–4].
HMGA1 functions as an architectural transcriptional factor, as it
regulates its target genes and microRNAs by direct DNA binding,
forming transcriptional complexes and altering the conformation of
transcription factors and chromatin structure [5–7]. HMGA1 is
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embryonic and hematopoietic stem cells [8].
HMGA1 was first associated with the neoplastic phenotype in rat
thyroid transformed cells [9] and has since been shown to lead to
neoplastic transformation [3]. Of its many roles, HMGA1 negatively
regulates TP53 [10] and promotes an undifferentiated pluripotent
stem-like cell state through the induction of SOX2, LIN28 and
cMYC [11]. HMGA1 also directly activates genes involved in tumor
growth, migration, invasion, resistance to drug-induced cell death and
epithelial-mesenchymal transition in cancer cells [12–15]. Indeed,
HMGA1 overexpression has been reported in carcinomas of the
colon, breast, pancreas, ovary, lung, esophagus and testis [16–25],
and it correlated with advanced stage, the presence of distant
metastases and poor survival in colorectal carcinomas [16,17].
Furthermore, HMGA1 expression levels have been found to increase
progressively from no expression in normal breast tissue, to moderate
expression in hyperplastic lesions to strong overexpression in ductal
carcinomas [18], and to increase from weakly expressed in ovarian
carcinomas with low invasive potential to be highly expressed in
invasive carcinomas [21].
The HMGA1 locus (6p21.3) is gained in around 40% of
hepatocellular cancers (HCCs) [26], and an early study suggested
that HMGA1 is expressed in 30% of primary HCC on the mRNA
level and 13% on the protein level [27]. Furthermore, HMGA1
mRNA expression was found to correlate with Edmondson grade and
worse prognosis [27]. The functional significance of HMGA1
overexpression, however, has not been assessed. In this study, we
evaluated HMGA1 mRNA expression levels in a cohort of HCC
needle biopsies matched with their corresponding cirrhotic tissues
and normal liver donors by gene expression microarrays and
quantitative real-time PCR (qRT-PCR). Using tissue microarray
(TMA) technology, we further corroborated our results at the protein
level in a large independent collection of 379 specimens including
normal liver, cirrhotic and HCC tissues. Finally, we showed that
HMGA1 overexpression promoted tumor growth and migration
potential in liver carcinogenesis.
Materials and Methods
Ethics
The study has been approved by the Institutional Review Board of
the Institute of Pathology, University Hospital, Basel and the Ethics
Committee of Nordwest/Central Switzerland (EKNZ).
Re-analysis of Transcriptomic Profiling Data
HMGA1 expression was evaluated in 59 HCC needle biopsies, 37 of
which were matched with their corresponding non-neoplastic liver
parenchyma (cirrhotic tissues) and 5 normal liver donors using
transcriptomic data our group previously published (GSE64041) [28].
CEL files were normalized using the Qlucore software (Qlucore AB,
Lund, Sweden) [29].HMGA1 expression was extracted for each sample.
Expression of HMGA1 by Quantitative Real-Time PCR
RNA from 13/37 matched biopsies of HCC and their cirrhotic tissue
previously subjected to transcriptomic profiling [28] was available and
subjected to qRT-PCR analysis (Supplementary Methods).
Immunohistochemistry
Immunohistochemical staining of HMGA1 was assessed on a
TMA of an independent cohort of 192 HCCs, 108 cirrhotic tissuesand 79 normal liver samples, as previously described [29,30].
Follow-up information was available for 100/192 patients with HCC.
HMGA1 antibody was raised against a synthetic peptide as previously
reported [19]. Staining was performed as described previously [19,25]
(Supplementary Methods). Samples with ≥5%HMGA1-positive cells
were considered HMGA1-positive [19,25]. Staining was indepen-
dently scored by three pathologists (DB, FT and LT).
Statistical Analysis
Statistical analyses for categorical and non-categorical variables
were performed using Chi-Square/Fisher's Exact and Mann–Whitney
U/Student's t tests. Analysis of the variance was performed using the
ANOVA test. Correlation was assessed using Spearman's rank
correlation. Survival analyses were performed using the Kaplan–
Meier method and the log rank test. All tests were two-sided. P-values
b0.05 were considered statistically significant. All analyses were
performed using Graphpad Prism 6.0 (Graphpad Software, Inc., La
Jolla, CA) or SPSS v.20 (Endicott, New York, NY).
Cell Lines
Four liver cancer cell lines (PCL5, HEPG2, SNU449 and
SNU182) were used for in vitro experiments. All cell lines were
negative for mycoplasma infection using the Universal Mycoplasma
Detection kit (ATCC, Manassas, VA). Culture conditions are
described in Supplementary Methods.
Vector Construction, Transfections of Mammalian Cells and
Analysis of Transgene Expression
For overexpression, the pCDNA3.1-HMGA1 and the empty control
vectors were constructed as previously described [10]. For down-
regulation, the hairpin RNA interference plasmid for human HMGA1
(pLKO.1-HMGA1, TRCN0000018949) and the scramble control
pLKO.1-Puro plasmid (SHC002) were purchased from Sigma-Aldrich
(Sigma-Aldrich, St. Louis, MO). The expression of HMGA1 in stable
clones was evaluated by western blot (Supplementary Methods).
Proliferation Assay
Proliferation assays were performed using the xCELLigence
Real-Time Cell Analysis (RTCA, ACEA Biosciences, San Diego,
CA, USA) system. Cell index values were calculated and normalized
by the RTCA Software Package v.1.2 (Supplementary Methods).
Numerical data were expressed as mean ± standard deviation.
Growth curves were analyzed using multiple t-tests, corrected for
multiple comparisons by the Holm-Šídák method (alpha: 0.05) using
GraphPad Prism 6.0 (Graphpad Software, Inc.).
Transwell Migration Assay
The transwell migration assay was used to assess the chemotactic
and migration capacity of cells. Cells were seeded in the upper part of
the transwell (8 μm pore membranes) of the 24-well plate and higher
serum content was placed in the lower compartment to attract cells to
migrate through the membrane. Cells that passed through the
membrane were fixed on the membrane using methanol (Supple-
mentary Methods). Fixed cells were stained with crystal violet and the
number of migrated cells was determined by the Benchmark Plus
microplate spectrophotometer (Bio-Rad, Hercules, CA, USA).
Soft Agar Colony Formation Assay
To assess cellular anchorage-independent growth in vitro, the soft
agar colony formation assay, a stringent method for the detection of
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the pLKO.1-HMGA1 transformed cells (Supplementary Methods).
Statistical analyses of the number and size of the colonies were
performed with GraphPad Prism 6.0 (Graphpad Software, Inc.) using
the Student's t test with Welch correction.
Results
HMGA1 mRNA is Frequently Up-Regulated in HCC
To determine the expression level ofHMGA1 inHCC,we re-analyzed
a published gene expressionmicroarray dataset of 59HCCbiopsies, 37 of
which were matched with their respective non-tumoral cirrhotic tissues
and 5 normal liver donor samples (GSE64041) [28].Notably, none of the
patients involved in the study received any therapeutic anti-cancer
treatment at the time of biopsy.
Our analysis showed a monotonic increase in HMGA1 mRNA
expression from normal liver tissues to cirrhotic tissues to HCCs
(P b .001; ANOVA test; Figure 1A), with increased expression inHCCs
compared to cirrhotic tissues and normal liver tissues (both P b .0001,
Mann-WhitneyU tests) and in cirrhotic tissues compared to normal liver
tissues (P = .026, Mann-Whitney U test; Figure 1A). Moreover,
HMGA1 expression levels were higher in Edmondson grades III/IV
than in grade II tumors (P b .0001, Mann-Whitney U test; Figure 1B)
and inHCCswithmetastasis (regional lymph node invasion and/or distantFigure 1. HMGA1 mRNA expression level using gene expression m
corresponding non-tumoral area (cirrhotic tissue) and normal liver sam
associated with and not associated with metastasis and (D) in HCCs
performed using Mann-Whitney U tests. P b .05 was considered staorgan involvement) than those without (P = .0084, Mann-Whitney U
test; Figure 1C). When stratified by underlying virus or alcohol
background, we found no difference inHMGA1 expression levels, except
that HCCs on a combination of virus and alcohol background showed
higher expression than HCCs on an alcohol background (P = .02,
Mann-WhitneyU test; Figure 1D).
To confirm the array-derived data, we evaluated theHMGA1mRNA
expression levels in 13 of the 37 paired HCCs and cirrhotic tissues for
which RNA was available. Consistent with the array-derived data, we
found that HMGA1 expression was higher in HCCs than in cirrhotic
tissues (P = .0119; paired Mann-WhitneyU test; Supplementary Figure
1A). Furthermore, HMGA1 expression levels from array-derived and
qRT-PCR data were highly correlated (r = 0.67, Spearman correlation,
Supplementary Figure 1B). Altogether, these results demonstrate that
HMGA1mRNA is overexpressed in HCCs than their matched cirrhotic
tissues and normal liver tissues.
HMGA1Protein Expression is AssociatedWithDisease Progression
and Poorer Survival in HCC
To corroborate our mRNA expression-derived results on the
protein level, we evaluated HMGA1 on a TMA of an independent
cohort of 192 HCCs, 108 cirrhotic tissues and 79 normal liver
samples [29,30]. Consistent with the mRNA expression analysis, the
percentage of HMGA1-positive cells increased monotonicallyicroarrays. Boxplots show HMGA1 expression (A) in HCC area,
ples, (B) in moderately and poorly differentiated HCCs, (C) in HCCs
stratified according to the etiology. Statistical comparisons were
tistically significant. EtOH: alcohol-related. ns: not significant.
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HCC (P b .0001; ANOVA test; Figure 2A) and were significantly
higher in HCCs and in cirrhotic tissues than in normal liver samples
(both P b .0001, Mann–Whitney U tests; Figs. 2a and 3). HMGA1
expression was also increased in Edmondson grades III/IV and II
HCCs compared to grade I HCCs (P = .037 and P = .018,
respectively, Mann–Whitney U tests; Figure 2B) with a monotonic
increase from grade I to grades III/IV (P = .026; ANOVA test).
Overall, 51%, 42% and 5% of HCCs, cirrhotic tissues and normal
liver samples expressed HMGA1, respectively (P b .0001,
Chi-squared test; Table 1) and 74%, 52% and 43% of Edmonson
grades III/IV, II and I HCCs expressed HMGA1, respectively (P =
.031, chi-squared test; Table 2). There was no association between
HMGA1 positivity and other clinicopathologic parameters, except
the male gender (Table 2).
We further explored whether HMGA1 positivity was associated
with clinical progression and outcome in HCCs. Of the 192 HCCs,
clinical follow-up was available for 100 patients. We found that
patients with HMGA1-positive HCCs were associated with earlier
disease progression and worse overall survival (P = .01 and P = .025,
respectively, log rank tests, Figure 2, C and D).Figure 2. HMGA1 protein expression level using TMA. Boxplots show
samples, and (B) in well, moderately and poorly differentiated HCCs.
expressed and did not express HMGA1 using the Kaplan-Meier m
Mann-Whitney U tests and (C and D) log-rank tests. P b .05 was conHMGA1 Overexpression Promote Tumor Growth and Migration
in In Vitro Models
To define whether HMGA1 would have oncogenic properties in
in vitro models of HCC, we tested the effect of its overexpression using
cDNA constructs in stable cultures of PCL5 and HEPG2 with low
HMGA1 endogenous expression and of its silencing in stable cultures of
SNU449 and SNU182 with high HMGA1 endogenous expression
(Supplementary Figure 2). Forced expression of HMGA1 in PCL5 and
HEPG2 led to increased cell growth (both P b .01, Figure 4, A and C),
while HMGA1 silencing in SNU449 and SNU182 showed reduced cell
growth (both P b .01, Figure 4, E and G) suggesting that HMGA1
expression promotes liver cancer cell growth. Using a transwell migration
assay, forced expression of HMGA1 in PCL5 and HEPG2 resulted in
increased cell migration (both P b .05, Figure 4, B and D) and
conversely,HMGA1 silencing in SNU449 and SNU182 led to decreased
cell migration (both P b .01, Figure 4, F and H).
We next investigated whether modulating HMGA1 expression
would alter the transformation capacity of liver cancer cells. By
assessing the impact of HMGA1 on anchorage-independent growth
on soft agar, we found that PCL5 and HEPG2 cells stably
overexpressing HMGA1 led to increased number and size of coloniesHMGA1 expression (A) in HCCs, cirrhotic tissues and normal liver
(C) Disease-free and (D) overall survival of patients with HCCs that
ethod. Statistical comparisons were performed using (A and B)
sidered statistically significant. ns: not significant.
Figure 3. Representative micrographs of HMGA1 protein staining. Representative micrographs of (A) negative, (B) moderate and (C) high
HMGA1 expression in cirrhotic tissues, and of (D) negative, (E) moderate and (F) high HMGA1 expression in HCC. All the micrographs
were taken at 20×.
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B). By contrast, down-regulating HMGA1 in stable clones of SNU449
and SNU182 led to decreased number and size of colonies (both at
P b .001, Student t tests with Welch correction; Figure 5, C and D).
Taken together our results suggest that, in line with previous
reports in other cancer entities, HMGA1 overexpression plays a
pivotal role in cell viability enhancing cell growth and migration and
induces transformation by anchorage-independent growth in liver
cancer cell lines.
Discussion
In this study, we demonstrated in two independent cohorts thatHMGA1
levels monotonically increased through the stages of progression from
normal liver to cirrhosis to HCC, both at the mRNA and the protein
levels and that HMGA1 protein expression was associated with poor
disease-free and overall survival. Our hypothesis that HMGA1 is a driver
of progression of HCC is supported by our functional evidence that
HMGA1 promoted cell growth, migration and transformation in liver
cancer cell lines. These results provide evidence that HMGA1 confers a
neoplastic advantage to liver cancer cell lines.
Of particular interest is that HMGA1 is expressed in 42% of cirrhotic
tissues. HMGA1 expression has been observed in other preneoplastic







Normal Liver (n = 79) 75 4 5%
b.0001Cirrhotic tissue (n = 108) 63 45 42%
HCC (n = 192) 95 97 51%
Statistical Comparison was Performed Using Chi-Squared Testsias and breast hyperplasia [16,18,19]. In fact, a similar pattern of
monotonically increasing HMGA1 expression through progression has
been found in normal colon epithelium, colon adenoma and colorectal
carcinoma [16] and in normal pancreatic tissue, pancreatic intraepithelial
neoplasias and invasive ductal adenocarcinoma of the pancreas [19].
Crucially, the substantial proportion of cirrhotic tissues showing high
HMGA1 expression suggests that although HMGA1 is a driver of
progression, it is not a specific biomarker for HCC.
Consistent with the reported survival differences between HCCs that
did or did not express HMGA1 mRNA [27], we found that 51% of
HCCs were HMGA1-positive by IHC and that HMGA1 proteinM stage .2141 16 11 41%
Multifocality
No 41 43 51%
1Yes 49 52 51%
Vascular Invasion
No 53 53 50%
.526Yes 28 35 56%
Etiology
EtOH 17 19 53%
.788
Virus 43 54 56%
Other 4 3 43%
Edmondson grade
I 44 33 43%
.031
II 42 45 52%
III/IV 6 17 74%
Statistical Comparisons were Performed Using Chi-Squared Tests
Figure 4. Impact of HMGA1 on cell growth andmigration in in vitromodels. Effect of overexpression of HMGA1 in (A) PCL5 and (C) HEPG2
and down-regulation of HMGA1 in (E) SNU449 and (G) SNU182 on cell growth compared to cells transfected with empty vector control.
Effect of overexpression of HMGA1 in (B) PCL5 and (D) HEPG2 and down-regulation of HMGA1 in (F) SNU449 and (h) SNU182 on cell
migration using Transwell assays compared to cells transfected with empty vector. Quantification was performed using a
spectrophotometer (FLU: Fluorescence spectroscopy of dyes). All experiments were performed in triplicates. Error bars, SD of the
mean. Statistical comparisons were performed using (A, C, E, G) Holm-Šídák-corrected multiple t tests and (B, D, F, H) Mann-Whitney U
tests. P b .05 was considered statistically significant.
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reported that 13% of HCCs were HMGA1-positive by IHC [27], the
higher frequency of HMGA1 positivity we found may be attributed to a
much larger cohort and a different antibody for immunodetection. In
terms of prognosis, we found that HMGA1 expression conferred worseprognosis, similar to the association of shorter survival in patients with
pancreatic ductal carcinoma that showed strong immunoreactivity [20],
and to the association of shorter disease-free and overall survival, as well as
an increased risk of distant metastases, in patients with
HMGA1-overexpressing uveal melanoma [31]. Here we demonstrated
Figure 5. Impact of HMGA1 on cell transformation in in vitromodels. Effect of overexpression of HMGA1 in (A) PCL5 and (B) HEPG2 and
down-regulation of HMGA1 in (C) SNU449 and (D) SNU182 on anchorage-independent growth. Quantification was performed by defining
the number and size of colonies. All experiments were performed in triplicates. Error bars, SD of the mean. Statistical comparisons were
performed using unpaired t-tests with Welch correction. P b .05 was considered statistically significant.
730 HMGA1 expression in hepatocellular carcinomas Andreozzi et al. Neoplasia Vol. 18, No. 12, 2016that HMGA1 is up-regulated in a substantial proportion of HCC and its
expression is associated with poor prognosis.
Previous studies showed that HMGA1 triggers oncogenic
transformation in cultured cells [32] and is associated with aggressive
cancer subtypes in animal models in several tumor types [20,33–35].
For example, in breast cancer cells, HMGA1 overexpression directly
activates genes involved in tumor cell migration and invasion [6] and
induces epithelial-to-mesenchymal transition [36]. Indeed, we
demonstrated in multiple liver cancer cell line models that the
HMGA1 increases tumor cell growth and migration and that
HMGA1 increased transformation potential in liver cancer cells.Nonetheless, these results are consistent with our and others' [27]
observation that HMGA1 expression was associated with Edmondson
grade and support the role of HMGA1 as a driver of progression.
This study has limitations. We studied HMGA1 protein
expression on TMA punches rather than whole sections, thus the
observed expression may not be representative of the individual tissue
samples. Despite this, given the large cohort, we expect that the
results to be representative on the cohort level. Secondly, the HCCs
in the TMA cohort were from resected materials rather than untreated
biopsies, thus the HMGA1 levels may have been altered as a result of
the surgical procedures and the long post-surgical hypoxia derived for
Neoplasia Vol. 18, No. 12, 2016 HMGA1 expression in hepatocellular carcinomas Andreozzi et al. 731the lack of blood perfusion. However, the analysis of the expression
microarrays of untreated liver biopsies is in agreement with the
findings at the protein level and it should be emphasized that the liver
biopsies, unlike resected materials, had never been subjected to
HCC-tailored therapies and are thus the most representative of the
natural biology of HCC. In conclusion, our findings demonstrated a
functional role for HMGA1 in the progression of HCC. Given
multi-faceted functions of HMGA1, further characterization of its
function in liver biology will provide novel insights into its
mechanisms of action in driving disease progression.
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